Sanofi

Genzyme Corporation

Aventis Pharma S.a.

Cendrine Lemoine

Béatrice Cameron

Catherine Prades

Huawei Qiu

Tarik Dabdoubi

Gary J Nabel

Ercole Rao

Ronnie Rong Wei

Christian Beil

Ling Xu

Zhi-Yong Yang

Lan Wu

Edward Seung

Jochen Beninga

Sunghae Park

Joerg Thomas Regula

Christian Lange

Joerg Birkenfeld

Wulf-Dirk Leuschner

Jonathan Rothblatt

Zhen Xing

Kara Carter

Marie Mandron

Gerhard Hessler

William Harold Brondyk

Patrice Denefle

Alan Thomas Remaley

Thomas Langer

Chantal Carrez

Nicolas Duverger

Angela Virone-Oddos

Katja Kroll

Peter Wonerow

Marie-Françoise Rosier-Montus

Karl-Christian Engel

Bryan H Brewer

Yangde Chen

Sandra Weil

Marion Schneider

Marielle Chiron Blondel

Nadja Spindler

Soraya Hoelper

Laurent Naudin

Sylvia Santamarina-Fojo

Yves Sabbagh

Yu Qiu

Yanfeng Zhou

Jana Albrecht

HyunSuk Cho

Cédric Barriere

Stéphane Guerif

Jacques Dumas

Alain Fournier

Jonathan Kingsbury

Brian Murray

Nathan Ostberg

Sanket Patke

Zichuan Zhang

Marie-Cécile Wetzel

Sevim Ozgur Bruderle

Ronnie Wei

The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Anti-CHIKV antibodies and uses thereof

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

PseudoFab-based multispecific binding proteins

Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.

Anti-CD38 antibodies and formulations

The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.

Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

FGFR3 antibodies and methods of use

The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.

Anti-CD38 antibodies and methods of use

Anti-CHIKV monoclonal antibodies directed against the E2 structural protein

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.

Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123

The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.

Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses

Growing community of inventors

Paris, France

Cendrine Lemoine